Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.1547
-0.0028-1.78%
Post-market: 0.15550.0008+0.52%19:59 EDT
Volume:131.30M
Turnover:24.05M
Market Cap:75.65M
PE:-0.24
High:0.1695
Open:0.1695
Low:0.1450
Close:0.1575
52wk High:3.87
52wk Low:0.1138
Shares:489.00M
Float Shares:301.00M
Volume Ratio:11.26
T/O Rate:43.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6496
EPS(LYR):-0.7455
ROE:-783.37%
ROA:-62.39%
PB:-0.80
PE(LYR):-0.21

Loading ...

Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate

Benzinga Earnings
·
May 18

U.S. Earnings Preview: Before Market Open May 18

Dow Jones
·
May 18

Gossamer Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Top News Today: Stocks Slide, Treasury Yields Rise on Strait, Inflation Fears

Dow Jones
·
May 16

Gossamer Bio Q1 net loss widens to $46.66 million; revenue rises to $16.96 million

Reuters
·
May 16

Gossamer Bio to report first-quarter results, host conference call and webcast

Reuters
·
May 15

Press Release: Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Dow Jones
·
May 15

Gossamer Bio Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
May 11

Gossamer Bio announces annual shareholder meeting webcast

Reuters
·
Apr 25

Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial

TIPRANKS
·
Apr 23

Gossamer Bio gets Nasdaq notice for failing $1 minimum bid price rule

Reuters
·
Apr 10

Gossamer Bio Lawsuit: Investors Allege Misleading Statements Ahead of Failed PAH Trial

TIPRANKS
·
Apr 04

Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS) and Biogen (BIIB)

TIPRANKS
·
Apr 02

Gossamer Bio Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Mar 23

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Mar 23

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)

TIPRANKS
·
Mar 19

Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss

Reuters
·
Mar 19

Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks

TIPRANKS
·
Mar 19

Portnoy Law Firm probes possible securities fraud at Gossamer Bio after 80.14% stock plunge

Reuters
·
Mar 18